Therapeutic and Diagnostic Interventions Based on Molecular Alterations in Acute Myeloid Leukemia (AML). Circos plot illustrating common molecular alterations in de novo AML in adults between the ages of 16-60 years of age (center). Molecularly targeted therapies based on the presence of certain mutations are shown around the Circos plot and include mutant-selective IDH1/2 inhibitors and FLT3 inhibitors and potentially the use of venetoclax and decitabine for IDH1/2 mutant and TP53-mutant AML, respectively. In addition to the use of mutations as therapeutic targets, certain mutations (such as mutant NPM1) may also be followed for minimal residual disease (MRD) assesment in AML. Not shown here are splicing factor mutations, which are more frequent in secondary AML and older patients and are being tested for selective sensitivity to spliceosome targeting agents.